Novartis (NOVN) Given a CHF 85 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. set a CHF 85 target price on Novartis (VTX:NOVN) in a report released on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.

A number of other brokerages have also recently weighed in on NOVN. Kepler Capital Markets set a CHF 86 price target on shares of Novartis and gave the stock a buy rating in a research report on Tuesday. Barclays set a CHF 75 price target on shares of Novartis and gave the stock a sell rating in a research report on Wednesday, January 16th. Goldman Sachs Group set a CHF 110 price target on shares of Novartis and gave the stock a buy rating in a research report on Monday, March 25th. HSBC set a CHF 86 price target on shares of Novartis and gave the stock a neutral rating in a research report on Wednesday, February 6th. Finally, Deutsche Bank set a CHF 85 price target on shares of Novartis and gave the stock a neutral rating in a research report on Friday, April 5th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of CHF 89.33.

Novartis has a 52-week low of CHF 72.45 and a 52-week high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Article: Understanding debt-to-equity ratio in fundamental analysis

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.